Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
Author:
Funder
Roche
Ministry of Health and Welfare
Novartis
Merck Sharp and Dohme
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference64 articles.
1. Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: meta-analyses of published studies;Kundu;Contemp Clin Trials,2017
2. Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials;Li;Clin Breast Canc,2018
3. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer;Michiels;Ann Oncol,2016
4. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival;Morita;J Natl Cancer Inst,2015
5. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial;Krop;Lancet Oncol,2017
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis;Cancer Medicine;2024-07
2. Efficacy and Safety of Trastuzumab Combined with Pertuzumab for Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer: A Meta-Analysis Study of Randomized Control Trials;Journal of Clinical Pharmacy and Therapeutics;2023-12-12
3. Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups;Frontiers in Oncology;2022-08-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3